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Abstract 30 
 31 
The mode of action of a group of glycosylated antimicrobial peptides known as glycocins 32 
remains to be elucidated. In the current study on one glycocin, sublancin, we identified the 33 
phosphoenolpyruvate:sugar phosphotransferase system (PTS) of Bacillus species as a key 34 
player in bacterial sensitivity. Sublancin kills several Gram-positive bacteria such as 35 
Bacillus species and Staphylococcus aureus, including methicillin-resistant S. aureus 36 
(MRSA). Unlike other classes of bacteriocins for which the PTS is involved in their 37 
mechanism of action, we show that the addition of PTS-requiring sugars leads to increased 38 
resistance rather than an increased sensitivity, suggesting that sublancin has a distinct 39 
mechanism of action. Collectively, our present mutagenesis and genomic studies 40 
demonstrate that, in particular, the histidine-containing phosphocarrier protein (HPr) and 41 
domain A of enzyme II (PtsG) are critical determinants for the bacterial sensitivity to 42 
sublancin.   43 
Introduction 44 
Bacteriocins are ribosomally synthesised peptides produced by a wide range of bacterial 45 
species. These bacteriocins endow the producing bacteria with a competitive advantage in 46 
their respective niche. Many bacteriocins are heavily post-translationally processed during 47 
their biosynthesis and these modifications are required for activity (1). Nisin is the best 48 
studied bacteriocin and belongs to the lantibiotic family (2). The mode of action of nisin 49 
involves binding to lipid II, which prevents further cell wall synthesis, followed by 50 
formation of pores within the membrane, leading to membrane permeabilization. Leakage 51 
of essential metabolites from these cells results in death of the bacteria. Targeting of lipid II 52 
by bacteriocins is a common mechanism of action (3-5). Other mechanisms include the 53 
targeting of phosphotransferase systems (6, 7), acting as Trojan horses (8, 9), parasitizing 54 
iron-uptake pathways (10), and causing the collapse of membrane potential together with 55 
leakage of ions and/or a decrease in intracellular ATP concentrations (11). There is much 56 
interest in bacteriocins for use in control of bacterial infections and therefore in their 57 
mechanisms of action. 58 
 59 
Sublancin is a bacteriocin produced by the Gram-positive soil bacterium Bacillus subtilis 60 
168. It is capable of killing several species of Gram-positive bacteria, such as Staphylococcus 61 
aureus, including methicillin resistant S. aureus (MRSA) (12). Sublancin is encoded on the 62 
SPβ prophage as a prepeptide by the sunA gene (13). The genes necessary for the synthesis 63 
of sublancin are also included in this region and are expressed from two promoters. The 64 
biosynthetic operon is made up of five individual genes, which are responsible for 65 
producing active sublancin. The sunT gene is responsible for the export of sublancin and 66 
cleavage of its leader sequence. Two thiol-disulfide oxidoreductases, encoded by bdbA (the 67 
only gene of the operon that is dispensable for active sublancin production) and bdbB, are 68 
responsible for creating the two disulphide bonds of sublancin. These disulphide bonds 69 
involve four of the five cysteine residues that are present in the sublancin peptide (14). The 70 
fifth cysteine residue undergoes glucosylation by the glucosyltransferase encoded by the 71 
sunS gene (15). The second promoter drives expression of a gene encoding the immunity 72 
protein SunI that is also required for the production of active sublancin by protecting the 73 
producing organism from sublancin (16).  74 
 75 
Sublancin is one of five bacteriocins that have so far been described as being S-76 
glycosylated. Glycocin F is produced by Lactobacillus plantarum (17), ASM1 is produced by 77 
Lactobacillus plantarum A-1 and is an orthologue of glycocin F with five different residues 78 
in the C-terminal tail (18, 19), and the putative products of Bacillus thuringiensis, 79 
thurandacin A and B, have been produced in vitro (20). Sublancin is modified on Cys22, 80 
with a β-S-linked glucose (15, 21). For glycocin F an S-linked N-acetylglucosamine (GlcNAc) 81 
is added to the C-terminal cysteine residue and the other modification is on an internal 82 
serine residue with an O-linked GlcNAc (17, 22). Like glycocin F, thurandacin B is 83 
glucosylated on two residues; a cysteine residue undergoes S-linked glucosylation, whereas 84 
a Ser is modified with an O-linked glucose moiety (20). Judged by homology searches to the 85 
bacteriocin sequence or the glucosyltransferase, many other Gram-positive bacteria appear 86 
to potentially encode such bacteriocins with much variation in sequence amongst them (15, 87 
17).  88 
 89 
The mechanisms by which glucosylated bacteriocins kill sensitive cells are currently 90 
unknown. Previous work has identified several genes in B. subtilis and S. aureus that alter 91 
the sensitivity to sublancin. The mscL gene encodes the large mechanosensitive channel 92 
and its deletion confers sublancin resistance in both S. aureus and B. subtilis (23). Addition 93 
of increased amounts of NaCl also results in increased resistance to sublancin, presumably 94 
due to the MscL channel being forced closed. This observation has led to speculation as to 95 
whether sublancin is able to enter the cell through this channel. Interestingly, since the 96 
connection between sublancin and MscL was reported, streptomycin has also been 97 
reported to use the MscL channel to enter the cell (24). In B. subtilis the alternative sigma 98 
factor σW is known to play a role in the resistance to sublancin through its regulation of the 99 
yqeZ-yqfA-yqfB operon (25). The role these genes play in resistance to sublancin is 100 
unknown, but it is likely to be at the cell surface due to their membrane localisation (26).  101 
 102 
In this study, we demonstrate that the phosphoenolpyruvate:sugar phosphotransferase 103 
system (PTS) of B. subtilis plays a major role in sensitivity to sublancin. In the case of other 104 
bacteriocins where the PTS was found to be involved, addition of the PTS-requiring sugars 105 
resulted in increased sensitivity to the respective bacteriocin. However, for sublancin, the 106 
addition of PTS-requiring sugars leads to increased resistance, suggesting that sublancin 107 
has a distinct mechanism of action.  108 
 109 
Materials and Methods 110 
 111 
Bacterial growth 112 
For all strains used in this study, see Table 1. B. subtilis 168, B. subtilis ATCC 6633 and B. 113 
halodurans C-125 were grown in Lysogeny Broth (LB) at 37 °C with vigorous shaking (250 114 
rpm) and on LB agar plates. B. subtilis was also grown on M9 agar plates (M9 as described 115 
(27), but with the addition of 1.5 % final concentration agar) with and without the addition 116 
of sugars at final concentrations of 0.3 % glucose, 0.4 % malate or 0.4 % citrate as specified 117 
below. The LB agar used for sublancin inhibition plate assays did not include NaCl. 118 
Antibiotics were used for selection when necessary at the following concentrations: 119 
spectinomycin 100 µg/mL, kanamycin 20 µg/mL, phleomycin 4 µg/mL, chloramphenicol 5 120 
µg/mL and erythromycin 2 µg/mL. Stock sublancin solutions were prepared using PBS. 121 
 122 
Production and isolation of sublancin 168 123 
Purification of sublancin from its natural producer, B. subtilis 168, was performed as 124 
previously reported (15). 125 
 126 
Strain construction 127 
Chromosomal DNA was prepared from B. subtilis 168 using a standard procedure as 128 
previously described (28). Deletion mutants in B. subtilis 168 were created as described by 129 
Tanaka et al. (29) and oligonucleotides used are shown in Table S1 in the supplemental 130 
material. B. subtilis 168 was transformed using PCR products or chromosomal DNA 131 
following a standard procedure as previously described (30). 132 
 133 
Minimum inhibitory concentration (MIC) determination 134 
MICs were determined by the broth dilution method (31). Serial dilutions of sublancin 135 
were prepared in sterile deionized water (SDW). Forty-eight well microtiter plates 136 
(Corning Costar) were utilized for both B. subtilis ATCC 6633 and Bacillus halodurans C-137 
125. The total volume of culture in each well was 300 μL; the experimental wells contained 138 
30 μL of 10x stock sublancin at defined concentrations and 270 μL of a 1-in-10 dilution 139 
(approximately 1 x 108 colony-forming units (CFU) mL-1) of a culture of indicator strain 140 
diluted in fresh LB growth medium. In addition, each plate contained several blanks (270 141 
μL fresh growth medium and 30 μL SDW) and control wells (270 μL of untreated 1-in-10 142 
diluted culture and 30 μL SDW). The optical density at 600 nm (O.D.600nm) was recorded at 143 
hourly intervals from 0 to 6 h with an additional measurement at 18 h using a BioTek 144 
Synergy 4H plate reader. Plates were incubated under vigorous agitation at 37 °C. The 145 
readings of triplicate experiments were averaged. Growth curves were developed using 146 
control (culture and SDW only) readings to ensure sufficient O.D. changes for accurate 147 
inhibition assessment. Curve fits for MIC determination were produced by fitting the data 148 
with Origin8.5 software using a dose-response curve with the equation: y = A1 + (A2 – A1) 149 
/ (1 +10(Logx0 – x)p), with p = variable Hill slope.  150 
 151 
Sublancin killing kinetics against sensitive Bacillus species  152 
Sensitive cultures were grown to mid log phase in LB medium as described above, 153 
transferred to 48-well microtiter plates (Corning Costar) and exposed to sublancin at 1x 154 
and 4xMIC. Immediately after the addition of sublancin, the O.D.600nm was determined using 155 
a BioTek Synergy H4 plate reader. The cultures were incubated for 6 h and the O.D.600nm 156 
was recorded every 30 min. To verify that cells were killed, CFU counting was performed 157 
by serial dilution and plating. 158 
 159 
  160 
Sublancin sensitivity screen of a gene deletion collection of B. subtilis  161 
Sublancin-induced growth inhibition assays were performed using the procedure 162 
described by Dorenbos et al (14), but with modification to enable the screening of large 163 
numbers of strains. Overnight cultures of B. subtilis mutants and background control strain 164 
were grown in 96-well microtiter plates in a plate shaker at 37 °C with shaking at 800 rpm. 165 
Bioassay dishes were prepared with LB agar without adding salt. The plates were 166 
thoroughly dried before being divided into 48 squares for inoculation. Cotton swabs were 167 
dipped into individual wells of the overnight culture before being spread on the 168 
appropriate square. Plates were allowed to dry, before spotting 2 µL of an overnight 169 
culture of the B. subtilis 168 wild-type strain in the centre of each inoculated square. Plates 170 
were incubated overnight and visual analysis was used to determine zones of inhibition 171 
that were smaller or larger than that of the background strain. Strains with altered zones of 172 
inhibition were checked a further three times to ensure the phenotype was reproducible. 173 
 174 
Sublancin sensitivity assay in liquid medium  175 
Overnight cultures of B. subtilis grown in LB were diluted 1:100 in the same medium and 176 
grown to O.D.600nm 0.5. The bacteria were then diluted 1:20 in a 96-well microtiter plate 177 
before growth was monitored in a Synergy4 Biotek plate reader every 10 min (37 °C, with 178 
shaking). When the bacteria reached O.D.600nm 0.185 (equivalent to 0.5 for a 1 cm path 179 
length), sublancin was added at the desired concentration, before resuming the monitoring 180 
of growth. Sugars were added at the following final concentrations: glucose 0.3%, malate 181 
0.4%, sucrose 0.3 %, fructose 0.3%, glycerol 0.3%, citrate 0.4%, galactose 0.4% and 182 
succinate 0.4%. 183 
 184 
Membrane integrity assay  185 
B. subtilis was grown to O.D.600nm 0.5, before purified sublancin was added at different 186 
concentrations (100 – 500 nM). As a positive control, nisin was added at 10 nM final 187 
concentration and a negative control sample contained no bacteriocin. Samples were taken 188 
at 30 and 90 min and prepared for LIVE/DEAD® BacLight™ analysis (Molecular Probes, 189 
Life Technologies) (32). Samples were monitored by flow cytometry using an Accuri C6. 190 
The percentages of cells with intact or reduced membrane integrity were calculated.  191 
 192 
Propidium iodide uptake 193 
Membrane integrity was also evaluated by measuring the uptake of propidium iodide (PI). 194 
B. subtilis ATCC 6633 and B. halodurans C-125 cultures were grown to a density of 4 x 106 195 
cells mL-1 and then diluted with fresh LB medium to an O.D.600nm of 0.1. Cells were 196 
transferred to tubes containing PI (final concentration 25 μM; Molecular Probes Inc., 197 
Leiden, NL), HEPES (1 mM), and sublancin (0, 0.2, 2.0, 20 μM) or nisin (0, 0.2, 2.0, 20 μM), 198 
incubated for 30 min at RT, and analysed. Data acquisition was performed with a BD 199 
Biosciences LSR II flow cytometer, using excitation at 488 nm with an argon laser and 200 
measurement of emission through a band-pass filter at 695/40 nm. A minimum of 50,000 201 
events was detected for each sample, and experiments were performed in triplicate. Data 202 
analysis to calculate the geometric mean fluorescence intensity (MFI) of gated cell 203 
populations was performed using FCS Express 3.00.0311 V Lite Stand-alone software. 204 
 205 
Generation of stable sublancin resistant mutants and resistance frequency 206 
determination 207 
Genetically stable, sublancin resistant mutants were generated by growing the sublancin 208 
susceptible strains B. halodurans C-125 and B. subtilis ATCC 6633 in LB as described above 209 
(no additional sugars added) until an O.D.600nm of 1.0 (mid log phase, 1 cm light path). The 210 
cultures were plated on agar plates containing 1x or 4x their respective sublancin MICs. 211 
Distinct colonies were observed by 24 h. Resistant colonies were picked, grown in LB and 212 
plated on LB plates containing sublancin at 4xMIC to confirm resistance. This procedure 213 
generated genetically stable sublancin mutants. The number of resistant mutants that 214 
emerged from each sublancin susceptible culture was obtained by generating a serial 215 
dilution of each culture. Each dilution was plated on sublancin-containing plates. The total 216 
number of cells was determined by plating an appropriate (10-5, 10-6, 10-7, 10-8, 10-9) 217 
dilution of the cultures on non-selective LB agar medium. Colonies from sublancin-218 
containing and non-selective plates were counted after 24 h of incubation. The resistance 219 
frequency was determined as the mean number of resistant cells divided by the total 220 
number of viable cells per culture. 221 
 222 
Single Nucleotide Polymorphism (SNP) detected by whole genome sequencing 223 
Genomic DNA (gDNA) of the wild-type B. halodurans C-125 and four different sublancin 224 
resistant isolates was extracted using an UltraClean® Microbial DNA isolation kit (MO 225 
BIO). The gDNAs thus obtained were sequenced using a HiSeq2000 Illumina sequencer, 226 
which generated close to 180 million single-reads per lane, for an overall coverage of 360x 227 
for the 5 MB genomes. All libraries were individually barcoded and constructed with the 228 
TruSeq Sample Prep kits (Illumina). The SNPs and the corresponding genes for resistant B. 229 
halodurans C-125 were identified. In addition, the wild-type B. halodurans C-125 strain was 230 
mapped to the published B. halodurans C-125 sequence (accession no. NC_002570.2) with 231 
CLC Genomics Workbench (CLC bio), using default parameters. A consensus sequence of 232 
the wild-type and reference genome was obtained and used for SNP detection in sublancin 233 
resistant mutants of B. halodurans.  234 
 235 
PCR amplification and validation of SNPs in sublancin resistant B. halodurans 236 
mutants  237 
PCR validation can serve as an iterative and informative process to modify and optimize 238 
the SNP filtering criteria to improve SNP calling (33). Primers flanking SNP-containing 239 
genes were synthesized and used for PCR amplification of the respective genes. The 240 
mutations reported herein were all confirmed by PCR (Table S2 in the supplemental 241 
material).  242 
 243 
B. halodurans C-125 gene expression profile 244 
A culture of B. halodurans C-125 was grown in LB at 37 °C with vigorous shaking until mid 245 
log phase, at which point the culture was split into two 150 mL cultures with one subjected 246 
to a sub-inhibitory concentration of sublancin (0.5xMIC). RNA isolation was performed 247 
using the RNeasy mini kit (Qiagen) and subsequently treated with RNase-Free DNase 248 
(Qiagen). The RNA was dissolved in RNase-free water and quantified using a NanoDrop 249 
2000c spectrophotometer (Thermo Scientific). For each sample (i.e. with and without 250 
sublancin), 20 μg of total RNA was isolated from three biological replicates. cDNA synthesis 251 
was performed using the SuperScript® Double-Stranded cDNA Synthesis Kit (Invitrogen) 252 
as per the manufacturer’s instructions (NimbleGen Arrays User’s Guide, Version 5.1) and 253 
quantified with NanoDrop. Total cDNA was labeled overnight with the One-Color DNA 254 
labeling kit (NimbleGen) as per the manufacturer’s instructions. Arrays were scanned using 255 
an Axon 4000B array scanner.  256 
A B. halodurans C-125 Nimblegen custom array, containing a probe set of 22 unique 45mer-257 
60mer oligonucleotide probes for each of the 4066 genes of this bacterium, was used. 258 
NimbleScan software (v 2.6.0.0, Roche NimbleGen) was used to generate one normalized 259 
value per probe set using the RMA algorithm (background correction, normalization and 260 
summarization; data not logged). The data were then imported into R (34) using the limma 261 
package (35) and log2-transformed. Statistical analysis for differential expression between 262 
the mutant and wild-type groups was performed, taking into account the correlation due to 263 
processing batch (36, 37). Raw p-values were corrected for multiple hypotheses testing 264 
using the False Discovery Rate method (38). Annotation for the probe sets was primarily 265 
provided by Nimblegen and included BH ids (e.g., BH0001), gene names, descriptions, 266 
genomic locations and URL links to NCBI. Entrez Gene IDs and official gene symbols were 267 
downloaded from the B. halodurans genome record in NCBI (NC_002570). For analysis, we 268 
filtered to identify those genes that were altered by at least a 1.5-fold change in 269 
transcription (up-regulation and down-regulation). For data mining, we used DAVID 270 
bioinformatics resources that consist of an integrated biological knowledge base and 271 
analytic tools that use the results from the statistical analysis to explore and interpret gene 272 
regulation data (39). 273 
 274 
Results 275 
Sublancin displays sub micromolar MICs against Bacillus strains 276 
The antibacterial activity of sublancin against selected Bacillus strains was first determined 277 
by solid agar diffusion assays containing sublancin at a range of concentrations (0.097 μM – 278 
50 μM). After confirmation that B. subtilis ATCC 6633 and B. halodurans C-125 were 279 
sensitive, the minimum inhibitory concentrations (MICs) were determined by the broth 280 
dilution method (40, 41). A series of dilutions of sublancin (0.097 μM – 50 μM) were made 281 
and incubated with a defined number of bacterial cells in LB medium. Plates were 282 
incubated for 18-24 h at 37 °C, and growth was assessed by measuring the optical density 283 
of each well at O.D.600nm. The MICs were determined by fitting the data to a dose-response 284 
curve. The MICs of sublancin against B. halodurans C-125 and B. subtilis ATCC 6633, in 285 
liquid cultures, were 0.312 μM and 0.625 μM, respectively (Fig. S1 in the supplemental 286 
material).  287 
 288 
Bactericidal activity of sublancin 289 
One element for consideration, when trying to understand how an antimicrobial compound 290 
functions, is whether it is bactericidal or bacteriostatic. Furthermore, some bacteria lyse 291 
after being killed, others lyse immediately, and yet others undergo non-lytic death (42, 43). 292 
The ability of sublancin to kill or arrest the sensitive Bacillus strains was therefore 293 
evaluated. B. subtilis ATCC 6633 and B. halodurans C-125 cultures were grown to mid log 294 
phase, transferred to a 48-well plate and exposed to sublancin (1x and 4x MIC). After the 295 
addition of sublancin, the O.D.600nm was monitored periodically. After a 6-hour incubation 296 
period, the B. halodurans C-125 and B. subtilis ATCC 6633 cultures showed a decrease in 297 
optical density, suggesting sublancin has bactericidal activity (Fig. 1). To verify whether 298 
sublancin’s activity was bactericidal, CFUs were determined by plating, which confirmed 299 
the bactericidal activity observed by O.D. readings. The decrease in optical density was not 300 
nearly as large as the decrease in CFUs, which implies that sublancin kills without 301 
immediate lysis.  302 
 303 
Sublancin does not affect the integrity of the cell membrane  304 
Some bacteriocins destabilize the membrane or form pores (4, 44). Nisin is the prototypical 305 
pore-forming bacteriocin, which binds to lipid II within the membrane (2). To determine 306 
whether sublancin affects membrane integrity, we challenged cultures of B. subtilis ∆SPβ, B. 307 
subtilis ATCC 6633 and B. halodurans C-125 with several different concentrations of 308 
sublancin. We monitored the membrane integrity of B. subtilis ATCC 6633 and B. 309 
halodurans C-125 by flow cytometric analysis, using the cell impermeable propidium iodide 310 
(PI) dye, after a 30 min exposure to sublancin. Our nisin control showed an increase in 311 
fluorescence due to membrane permeabilization, but sublancin did not, even at 312 
concentrations as high as 32xMIC for B. subtilis ATCC 6633 and 64xMIC for B. halodurans C-313 
125 (Fig. 2). We monitored the membrane integrity of B. subtilis ∆SPβ with the 314 
LIVE/DEAD® BacLight™ bacterial cell viability assay at 30 and 90 min after addition of 315 
sublancin (Fig. S2 in the supplemental material). At both time points we found no change in 316 
membrane integrity. When the same strain was exposed to nisin as a positive control, a 317 
dramatic loss of membrane integrity was seen already after 30 min incubation. Collectively, 318 
these experiments show that sublancin does not affect membrane integrity and likely acts 319 
through an alternative mechanism. 320 
 321 
Resistance frequency 322 
The manifestation of antibiotic resistance to clinically used antibiotics suggests that 323 
resistance is likely to develop against any antibacterial compound. It is useful however to 324 
analyze the frequency at which resistance to novel antibacterial compounds arises (45). 325 
The spontaneous resistance frequency is defined as the number of resistant mutants per 326 
total number of viable cells that grow after an established period of time. The resistance 327 
frequency of sublancin was determined by plating aliquots of bacterial culture onto agar 328 
containing the antibacterial compound at 4xMIC. Aliquots were also plated onto agar plates 329 
with no antibiotic to determine the number of viable bacterial cells in the liquid culture. 330 
The resistance frequencies determined were relatively high, with resistance frequencies of 331 
10-5 for B. halodurans C-125 and 10-6 for B. subtilis ATCC 6633. To verify that colonies 332 
observed were indeed resistant to the antibiotic, they were sub-cultured in sublancin-free 333 
LB media and plated on LB agar containing the antibacterial compound at a concentration 334 
of 4xMIC. For both strains, the plated resistant strains grew a full lawn.  335 
 336 
  337 
Identification of B. subtilis chromosomal regions that affect sensitivity to sublancin 338 
We aimed at finding genetic factors that affect sensitivity to sublancin. To do this we first 339 
employed the set of deletion mutants described by Tanaka et al. (29). These mutants were 340 
created in a strain in which the prophages of B. subtilis had been deleted, including SPβ. 341 
Therefore, all mutant strains lack the gene encoding the immunity protein for sublancin, 342 
sunI (46), making it an ideal collection of mutants for identifying interesting genomic 343 
regions with respect to sublancin sensitivity. During the screening, we used LB agar 344 
without NaCl, as it was previously shown that B. subtilis is more sensitive to sublancin in 345 
low osmotic conditions (23). The strains were plated in duplicate on the LB agar and 346 
spotted with 2 µL of an overnight culture of the sublancin-producing strain B. subtilis 168. 347 
We found strain JJS-DIn010, in which rsiW and sigW are deleted, to have increased 348 
sensitivity (i.e. a larger zone of clearing around the producing colony) (Fig. 3a). This finding 349 
is in concordance with previously reported observations (25), suggesting that our assay 350 
was able to identify strains with altered sensitivity. Another strain was identified (JJS-351 
DIn042), in which the genes ykvS, ykvT, ykvU, stoA, zosA, ykvY, ykvZ, glcT, ptsG, ptsH and ptsI 352 
were deleted. JJS-DIn042 was resistant to the effects of sublancin (Fig. 3a) under conditions 353 
where the ∆SPβ strain did not survive. Because of this interesting observation, we 354 
investigated this region further by constructing several different individual gene deletion 355 
mutants. This approach revealed that only the deletion of the pts operon (ptsGHI) results in 356 
resistance to sublancin (Fig. 3b and Table 2). In contrast, a deletion of glcT, which plays a 357 
regulatory role in the pts operon (47), did not result in sublancin resistance (Fig. 3b). PtsG 358 
is the major glucose transporter of the phosphotransferase system (48), and PtsH and PtsI 359 
are general components of the sugar transport system that phosphorylates the incoming 360 
sugar (49). PtsH is more commonly known as HPr, and we will refer to it as such in this 361 
work; PtsI is also called EI. In B. subtilis, the PTS transfers a phosphate group from 362 
phosphorylated PtsI to HPr, which in turn transfers the phosphate to a variety of different 363 
PTS permeases. For utilization of glucose, HPr transfers the phosphate to the IIA domain of 364 
the sugar permease PtsG. The IIA domain then phosphorylates the IIB domain of PtsG, 365 
which in turn transfers the phosphate to the incoming sugar. Lastly, the phosphorylated 366 
sugar moves into glycolysis. It is intriguing that the PTS was identified in our screen for 367 
sublancin sensitivity, as the most common PTS substrate is glucose whereas sublancin is 368 
glucosylated. A functional homologue of HPr is present in B. subtilis, i. e. Crh. We therefore 369 
tested a crh deletion mutant in the presence of sublancin, but no change in sensitivity was 370 
observed compared to the wild-type (data not shown), suggesting the sensitivity to 371 
sublancin is specifically dependent on HPr. 372 
 373 
Comparative genomics 374 
Bacteria often acquire stable resistance to antibiotics due to gene mutations. A comparative 375 
genomics analysis was therefore performed to identify the mutations that conferred 376 
resistance to B. halodurans C-125 after exposure to sublancin. The gDNA of the sensitive B. 377 
halodurans C-125 and of four of the spontaneous resistant mutants obtained as described 378 
above was extracted and sequenced using a HiSeq2000 Illumina sequencer. The wild-type 379 
B. halodurans strain was mapped to the published B. halodurans C-125 genome sequence 380 
(accession no. NC_002570.2) to generate a consensus sequence that was used for SNP 381 
detection in sublancin-resistant mutants of B. halodurans. Comparison of gDNA of the wild-382 
type sensitive strain with the four sublancin resistant mutants revealed several mutations. 383 
One strain contained three mutations in the intergenic region between the transcriptional 384 
anti-terminator (Locus tag: BH0845) and ptsG (Locus tag: BH0844), another strain 385 
contained a missense mutation in the gene for mannitol-1-phosphate 5-dehydrogenase 386 
(Locus tag: BH3851), and most interestingly, the three strains that did not have a mutation 387 
in the intergenic region mentioned above all had non-sense mutations in the gene for the 388 
glucose-specific transporter subunit IIC that is part of the multidomain protein PtsG (Table 389 
S2 in the supplemental material). The missense mutation prevents production of PtsG, and 390 
the three mutations in the intergenic region between the antiterminator and ptsG are 391 
predicted to considerably stabilize the structure of the terminator (Fig. S3 in the 392 
supplemental material), thus potentially also preventing ptsG transcription. Once more, 393 
these findings point to the PTS being important for sensitivity to sublancin. 394 
  395 
Gene expression profile by microarray analysis of B. halodurans C-125 396 
Antimicrobial resistance mutants provide valuable insights, but the information obtained 397 
from a resistance phenotype is not always representative of the identity of the target. We 398 
therefore also monitored changes in global gene expression upon exposure of B. halodurans 399 
C-125 to sublancin.  400 
The expression profiles revealed four genes that are part of sulfur metabolism that are 401 
highly up-regulated (changes from 9-14 fold, Table S3 in the supplemental material). The 402 
analysis also revealed up-regulated genes involved in transmembrane transporter 403 
activities, whereas genes involved in amino sugar and nucleotide sugar metabolism were 404 
up- and down-regulated. Interestingly, the genes for HPr and for PtsG that were also 405 
identified in the set of deletion mutants and in the comparative genomics analysis were 406 
down-regulated (Table S3 in the supplemental material) as was another PTS protein that is 407 
homologous to YpqE in B. subtilis, a putative phosphotransferase enzyme IIA component 408 
(50). These data again suggest that, like in B. subtilis, the PTS is involved in the sensitivity of 409 
B. halodurans towards sublancin. 410 
 411 
Addition of PTS sugars to the growth media results in increased resistance to 412 
sublancin 413 
Several bacteriocins have previously been shown to target PTS proteins as part of their 414 
mode of action. In these reported cases, addition of the relevant sugar resulted in an 415 
increased sensitivity to the bacteriocin (6, 7, 11). This effect is due to elevated uptake of the 416 
respective bacteriocins via the PTS. We therefore investigated whether this was also true 417 
for sublancin. The PTS is able to use many sugars, employing a different transporter for 418 
each sugar together with the HPr and PtsI proteins. Once the sugar is phosphorylated, it 419 
moves into glycolysis at the relevant metabolic junction. To investigate the influence of 420 
added sugars, B. subtilis ∆SPβ cultures were diluted in LB media (without NaCl) containing 421 
different sugars and grown in 96-well microtiter plates with shaking to an O.D.600nm 0.5 422 
before addition of sublancin at the MIC of 200 nM, as measured for this strain under these 423 
conditions. The presence of the PTS sugars glucose, sucrose and fructose, prevented the 424 
growth inhibition imposed by sublancin (Fig. 4a) since no significant reduction in O.D. was 425 
observed. In contrast, the non-PTS sugars citrate, galactose and succinate had no influence 426 
on sublancin’s activity (Fig. 4b). The two exceptions were the non-PTS sugars glycerol and 427 
malate. In this respect it is noteworthy that the the glycerol kinase GlpK requires 428 
phosphorylation by HPr for glycerol utilization (48, 51). Malate is a preferred carbon 429 
source for B. subtilis and is known to influence the carbon catabolite repression response 430 
(52). In this context it is noteworthy that a decrease in antimicrobial activity was also 431 
reported for glycocin F upon supplementation of the media with GlcNAc, which is the sugar 432 
that is attached to glycocin F at two positions (17). 433 
To further delineate the effects of sugars on sublancin sensitivity, purified sublancin was 434 
spotted onto lawns of B. subtilis ∆SPβ, which were grown on agar plates containing the 435 
defined M9 minimal medium supplemented with glucose, malate or citrate. When glucose 436 
was present the cells were always resistant to sublancin. In contrast, with citrate a large 437 
zone of clearing was observed. In the presence of malate an intermediately sized zone of 438 
inhibition was observed. This observation underpins the view that the carbon source 439 
affects the sensitivity to sublancin (Fig. S4 in the supplemental material). 440 
 Since glucose was found to prevent the effect of sublancin, we wondered whether it would 441 
be possible to rescue sublancin-treated cells by addition of glucose. We therefore grew the 442 
bacteria on LB medium (with NaCl) and added sublancin at O.D.600nm 0.5. The cells were 443 
then incubated for 30 min before addition of the same PTS and non-PTS sugars as in the 444 
previous experiment (Fig. 4c and d). Glucose almost instantaneously rescued the cells from 445 
the growth inhibition that sublancin imposed on the cells. Fructose also rescued the cells, 446 
but to a smaller extent than glucose. The non-PTS sugar glycerol rescued the cells in a 447 
similar manner to fructose. Malate was also able to rescue the cells, but this took 448 
approximately 100 min following the addition of the sugar, whereas the effect for glycerol 449 
and fructose was observed immediately after the addition of the respective sugar. In 450 
contrast, the addition of the other non-PTS sugars or sucrose had no effect on the survival 451 
of the bacteria.  452 
The observed rescue of growth by addition of the different PTS sugars and glycerol 453 
suggests that the PTS transporter is not being irreversibly inactivated by sublancin, but 454 
perhaps instead sublancin affects the pathway that leads to phosphorylation of the sugar. 455 
The addition of sublancin and the PTS sugar at the same time could result in competition 456 
for phosphorylation of the sugar or the glucose on sublancin (or its metabolite). With this 457 
in mind we looked at the phosphorylation sites on the HPr protein. 458 
 459 
Phosphorylation of HPr is responsible for sensitivity to sublancin 460 
The HPr protein is phosphorylated on two sites. The first, His15, is phosphorylated by PtsI. 461 
HPr then transfers the phosphate group to PtsG, and the phosphate is subsequently used to 462 
phosphorylate the incoming sugar. The second, Ser46, is phosphorylated by HPr kinase 463 
(HPrK) in conditions of large glycolytic flux. This phosphorylation subsequently allows HPr 464 
to form a complex with the catabolite control protein A (CcpA). This HPr-CcpA complex 465 
mediates carbon catabolite repression by binding to its cognate operator regions. To link 466 
sublancin sensitivity to one of these HPr-mediated processes, we tested two B. subtilis ∆SPβ 467 
strains with point mutations at one of the two HPr phosphorylation sites. As shown in Fig. 468 
5a, B. subtilis ∆SPβ carrying the S46A point mutation in HPr was fully sensitive to sublancin. 469 
In contrast, the strain carrying the H15A point mutation in HPr displayed an increased level 470 
of resistance to sublancin. This observation suggests that hprK and ccpA deletion mutants 471 
would remain sensitive to sublancin, since the carbon catabolite-repressing function of HPr 472 
is not affected. This prediction was indeed confirmed, as the deletion of either of these two 473 
genes had no effect on sublancin sensitivity (Fig. 5b). Also, the addition of glucose to the 474 
∆ccpA mutant conferred resistance to sublancin (not shown), providing further evidence 475 
that it is not the carbon catabolite-repressing branch of HPr regulation that leads to 476 
sublancin sensitivity. Instead, it seems to be the PTS branch involving the H15 477 
phosphorylation site that is responsible for the effects on sublancin sensitivity. However, 478 




Sublancin is a bacteriocin that was recently found to be glucosylated as part of its 483 
maturation process and this glucosylation is required for activity (15). We show in this 484 
study that sublancin is bactericidal and that it does not kill by pore formation or disruption 485 
of membrane integrity. Four different lines of evidence point towards the 486 
phosphoenolpyruvate:sugar phosphotransferase system as a factor affecting the activity of 487 
the bacteriocin. Experiments with deletion mutants of B. subtilis identified PtsG, HPr, and 488 
PtsI, but not GlcT and Crh, as important for sensitivity to sublancin. In addition, three of 489 
four B. halodurans sublancin-resistant mutants contained stop-codon mutations within the 490 
ptsG gene, with the fourth resistant strain having three mutations that potentially interfere 491 
with ptsG expression. The transcriptional profile also indicated a strong down-regulation of 492 
PTS genes upon exposure to sublancin and, lastly, addition of PTS sugars decreased the 493 
sensitivity to sublancin.  494 
 495 
The PTS has been previously described as affecting sensitivity to other bacteriocins, 496 
including dysgalacticin and lactococcin A (6, 7, 53). Dysgalactin appears to bind to the 497 
glucose and mannose transporters of the PTS (7). Dysgalacticin was shown to block the 498 
uptake of glucose and the non-metabolisable analog 2-deoxyglucose, and also to perturb 499 
the membrane of the cell causing the dissipation of membrane potential (7). This activity 500 
appears to be different from the mechanism used by sublancin as addition of glucose or any 501 
other PTS sugar blocked the killing activity of sublancin and membrane disruption was not 502 
observed. Lactococcin A also uses components of the mannose PTS in its mode of action. 503 
Lactococcin A binds to the membrane-located complex of the IIC and IID subunits of the 504 
mannose transporter (6), resulting in dissipation of the membrane potential (44). Like the 505 
observations with dysgalactin, decreased growth rates were observed for cells grown with 506 
mannose or glucose as the sole carbon source in the presence of lactococcin A (6). The 507 
current study suggests that sublancin is also functioning in a different manner to 508 
lactococcin A, since the studies with gene deletion strains and spontaneous resistance 509 
mutants both point at the phosphorylation components of the PTS as being key to 510 
sublancin sensitivity rather than the membrane components. When we monitored 511 
sublancin susceptibility using M9 minimal medium supplemented with glucose as the 512 
single carbon source, cells were completely immune to the effects of sublancin. A third 513 
bacteriocin, the circular molecule garvicin ML requires the maltose-binding protein for 514 
activity. Growth in media where the sole carbon source is either maltose or galactose again 515 
resulted in increased sensitivity to this bacteriocin (54). 516 
 517 
Two regions of the B. subtilis chromosome have now been identified that result in 518 
resistance to sublancin. The first being mscL, encoding a mechanosensitive channel as 519 
described by Kouwen et al. (23), and in this work the proteins encoded by the ptsGHI 520 
operon. Several scenarios may describe the mechanism by which sublancin is interacting 521 
with the PTS. Firstly, it is intriguing that it is the glucose transporter that was identified, 522 
given that sublancin is modified with an S-linked glucose moiety. The glucose moiety on 523 
sublancin could potentially be recognised by the transporter to facilitate entry into the cell 524 
or potentially to kill it through its interaction with this system. A competition between the 525 
sublancin and glucose could explain the observed decrease in sensitivity upon addition of 526 
glucose. We note that HPr and domains IIAB of PtsG are located in the cytoplasm (Table S4 527 
in the supplemental material), and hence for this mechanism to be correct, the glucose on 528 
sublancin would have to traverse the transporter or bypass the glucose transporter via the 529 
MscL channel. In this respect it is noteworthy that the other sugars that were able to 530 
protect the bacteria from sublancin are either gluconeogenic, or feed into glycolysis lower 531 
down the pathway, therefore possibly bypassing the need for the glucose transporter. 532 
When we tested strains that express variants of the HPr protein with point mutations that 533 
remove the phosphorylation sites, the mutation that led to increased resistance to 534 
sublancin was H15A. Phosphorylation of His15 is responsible for transferring a phosphate 535 
group to the incoming PTS sugar. This points towards a critical role of phosphorylation in 536 
the growth inhibition by sublancin and seems to suggest that sublancin may need to be 537 
phosphorylated upon its entry into the cell in order to exert its bactericidal effect. 538 
Interestingly, bacterial growth was rescued when PTS sugars were added to the growth 539 
medium 30 min after the challenge with sublancin. This finding implies that either the 540 
specific growth-inhibiting mechanism employed by sublancin is reversible, or that the 541 
addition of the PTS sugars results in the cell using a different biological process that allows 542 
survival.   543 
 544 
In conclusion, we show that sublancin exerts its bactericidal effects in a novel manner. At 545 
present it is not clear how exactly sublancin is interacting with the PTS and several 546 
questions remain for future research. Is there a physical interaction between sublancin and 547 
the PTS in the inhibited cells? Is there a link between the PTS and the MscL channel? How is 548 
sublancin actually inhibiting growth of the cell? How does the strong structural similarity 549 
of glycocin F and sublancin fit into the mechanism and what role does the three-550 
dimensional structure of the peptide components of these glycocins play (21, 22). In a time 551 
where bacteria are becoming resistant to the antimicrobial compounds that we currently 552 
use in clinical practice, research to understand how infections can be fought in alternative 553 
manners is essential. The apparently novel mechanism by which sublancin kills sensitive 554 
species of bacteria may therefore offer biological insights for the development of new 555 
antimicrobial strategies. Whether the mechanism identified in Bacillus is also operational 556 
in sensitive pathogens, such as S. aureus and Listeria monocytogenes, requires further in-557 
depth analyses.  558 
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Figure Legends 789 
 790 
Figure 1. Growth inhibition of B. subtilis ATCC 6633 and B. halodurans C-125 by 791 
sublancin 168. (a) Time-dependent changes in O.D.600nm of cultures of B. subtilis ATCC 792 
6633 in the absence (circles) or presence of sublancin 168 at 1xMIC (squares) and 4xMIC 793 
(triangles). (b) Aliquots of the cultures in panel (a) were analysed for colony forming units 794 
(CFUs). (c) Time-dependent changes in O.D.600nm of cultures of B. halodurans C-125. The 795 
same symbols are used as in panel (a). (d) Aliquots of the cultures in panel (c) were 796 
analysed for CFUs.  The mean values of the data from one experiment conducted in 797 
triplicate are shown. The data are representative of three independent experiments. Error 798 
bars indicate standard deviations. When error bars are not visible, they were a smaller 799 
than the size of the symbol used. 800 
Figure 2. Membrane integrity assays by measuring propidium iodide (PI) uptake. 801 
Addition of sublancin at the indicated concentrations (black bars) does not alter the 802 
membrane permeability of (a) B. halodurans C-125 and (b) B. subtilis ATCC 6633. Nisin was 803 
used as positive control (grey bars). * indicates a P<0.05 between nisin (0.1 μM – 20 μM) 804 
treated cells relative to no drug. In all experiments in which the cells were exposed to 805 
sublancin, the increase in MFI relative to control was not statistically significant (P > 0.05). 806 
The means of the data from one experiment conducted in triplicate are shown. The data are 807 
representative of those from three independent experiments. Error bars indicate standard 808 
deviations. 809 
Figure 3. Deletion of the ptsGHI operon results in resistance to sublancin. (a) The B. 810 
subtilis strains described by Tanaka et al (29) were screened for increased and reduced 811 
sensitivity to sublancin. The parental strain of the collection is labelled as ‘master strain’. In 812 
JJS-DIn042 the region from ykvS to ptsI is deleted and in JJS-DIn010 rsiW and sigW are 813 
deleted. (b) Growth curves of mutant strains with individual deletions of the genes that are 814 
responsible for the resistance in strain JJS-DIn042. Upper panel - Blue line – B. subtilis 815 
∆SPβ, green line - B. subtilis ∆SPβ-glcT. Lower panel - black line - B. subtilis ∆SPβ-ptsG, red 816 
line - B. subtilis ∆SPβ-ptsH, orange line B. subtilis ∆SPβ-ptsI. Solid lines – no sublancin. 817 
Dotted lines – 200 nM sublancin added at 100 min as indicated by the vertical grey line. 818 
Deletion of any of the genes within the ptsGHI operon results in resistance to sublancin. 819 
Deletion of the gene encoding the transcriptional anti-terminator glcT has no effect on the 820 
sensitivity of B. subtilis to sublancin. The means of the data from one experiment conducted 821 
in triplicate are shown. The data are representative of those from three independent 822 
experiments. 823 
Figure 4. Addition of PTS sugars to LB blocks growth inhibition by sublancin (a) 824 
Growth curves of B. subtilis ∆SPβ in LB medium with salt with added PTS sugars. Blue line – 825 
no addition of sublancin, red line – addition of sublancin, black solid line – addition of 0.3% 826 
glucose, black dotted line – addition of 0.3% fructose, black long dashed line – addition of 827 
0.3% sucrose, black short dashed line – addition of 0.3% glycerol. Sublancin was added at 828 
120 min as indicated by the vertical grey line. (b) Growth curve of the ∆SPβ strain in LB 829 
medium with addition of non-PTS sugars. Blue line – no addition of sublancin, red line – 830 
addition of sublancin, green line – addition of 0.4% malate, grey short dashed line – 831 
addition of 0.4 % citrate, grey dotted line – addition of 0.4% galactose, grey solid line – 832 
addition of 0.4% succinate. (c) Growth curve of the ∆SPβ strain with sublancin added at 833 
150 min followed by the addition of PTS and non-PTS sugars 30 min later as depicted by 834 
the two vertical lines, respectively. Blue line – no sublancin, blue dashed line – addition of 835 
sublancin, black line – 0.3% glucose, purple line – 0.3% fructose, orange line – 0.3% 836 
glycerol, green line - 0.4% malate, (final concentration of sugars shown). (d) Growth curve 837 
of the ∆SPβ strain with sublancin added at 150 min followed by the addition of PTS and 838 
non-PTS sugars 30 min later as depicted by the two vertical lines, respectively. Blue line – 839 
no sublancin, blue dashed line – addition of sublancin, grey line – 0.4% citrate, red line – 840 
0.3% sucrose, pink line – 0.4% galactose, green line – 0.4% succinate (final concentration of 841 
sugars shown). The means of the data from one experiment conducted in triplicate are 842 
shown. The data are representative of those from three independent experiments. 843 
Figure 5. The H15A mutation in HPr results in increased resistance to sublancin. (a) 844 
The two phosphorylation sites in the HPr protein were mutated individually to alanine 845 
residues. The growth curves of the resulting strains are shown, with 200 nM sublancin 846 
added at 120 min as depicted by the vertical line. Blue line - B. subtilis ∆SPβ, grey line - B. 847 
subtilis ∆SPβ-H15A, black line - B. subtilis ∆SPβ-S46A. Solid line – no sublancin. Dashed line 848 
– plus sublancin. (b) Blue line - B. subtilis ∆SPβ, grey line - B. subtilis ∆SPβ-hprK, black line - 849 
B. subtilis ∆SPβ-ccpA. Solid line – no sublancin. Dashed line – plus sublancin. The ∆ccpA and 850 
∆hprK mutations have no effect on the sensitivity of the cells to sublancin. 200 nM 851 
sublancin added at 120 min. The means of the data from one experiment conducted in 852 









Table 1. Strains  861 
Strain Genotype Reference 
168 Wild-type B. subtilis strain Laboratory 
Collection 
∆SPβ Wild-type B. subtilis 168 strain lacking the entire 
SPβ prophage  
(14) 
C-125 Wild-type B. halodurans (55) 
ATCC 6633 Wild-type B. subtilis (56) 
168 Deletion 
collection 
Collection of B. subtilis mutants lacking large 
genomic regions 
(29) 
∆SPβ::cat Chloramphenicol selectable ∆SPβ prophage 
mutant of B. subtilis (14)  
∆yvkS-yvkW B. subtilis ∆yvkS-yvkW::phleo This study 
∆ykvY-glcT B. subtilis ∆ykvY-glcT::phleo This study 
∆ptsG-ptsI B. subtilis ∆ptsG-ptsI::phleo This study 
∆SPβ-QB5435 B. subtilis ∆pstG::cat; QB5435 → SPβ (47) 
∆SPβ-MZ303  B. subtilis ΔptsH::cat; MZ303 → SPβ (57) 
∆SPβ-GP864  B. subtilis ∆ptsI::ermC; GP864 → SPβ (58) 
∆SPβ-QB5407  B. subtilis ∆ccpA::spec; QB5407 → SPβ (59) 
∆SPβ-GP202  B. subtilis ∆hprK::spec; GP202 → SPβ  (60) 
∆SPβ::cm-
GP506 
B. subtilis ptsH H15A; SPβcm → GP506 (61) 
∆SPβ::cm-
GP507  
B. subtilis ptsH S46A; SPβcm → GP576 (62) 
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Table 2.  Phenotype of single gene deletion strains of B. subtilis ∆SPβ upon 864 
















ykvZ  Sensitive 
glcT Sensitive
ptsG Resistant 
ptsH  Resistant 
ptsI  Resistant 





